BioLineRX
BLRX
28 hedge funds and large institutions have $43.4M invested in BioLineRX in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
52% more capital invested
Capital invested by funds: $28.5M → $43.4M (+$14.9M)
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more ownership
Funds ownership: 0.06% → 0.06% (+0%)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$8.79M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.33M |
| 3 |
Renaissance Technologies
New York
|
+$280K |
| 4 |
Morgan Stanley
New York
|
+$104K |
| 5 |
MCC
Malaga Cove Capital
Pv Estates,
California
|
+$34.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.51M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$828K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$743K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$126K |
| 5 |
PVH
Psagot Value Holdings
Tel Aviv,
Israel
|
-$103K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $2K | +$1.86K | +3 | New |
|
|
KF
27
Krilogy Financial
St. Louis,
Missouri
| $1K | – | – | – |
|
28
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
RE
29
RBC Europe
London,
United Kingdom
| $224 | – | – | – |
|
|
SM
30
Sabby Management
Miami Beach,
Florida
| – | -$2.51M | -4,915 | Closed |
|
|
DCM
31
DAFNA Capital Management
Los Angeles,
California
| – | -$828K | -1,634 | Closed |
|
|
32
Alyeska Investment Group
Chicago,
Illinois
| – | -$743K | -1,466 | Closed |
|
|
33
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$126K | -247 | Closed |
|
|
ARTA
34
A.R.T. Advisors
New York
| – | -$21K | -41 | Closed |
|
BLRX Hedge Fund Activity: Q3 2017 in Review
28 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q3 2017, worth a combined $43.4M — up 52% from $28.5M a quarter earlier.
Fund positioning in BLRX was balanced in Q3 2017: 5 funds opened new positions, 5 closed out, 8 added to existing stakes and 3 trimmed.
The largest buyer was BVF Inc, adding an estimated $8.79M. The largest seller was Sabby Management, exiting entirely with an estimated $2.51M sold.
- 28 institutional investors held BioLineRX (BLRX) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $43.4M of BioLineRX stock for Q3 2017, up 52% quarter-over-quarter.
- 5 funds opened new BioLineRX positions in Q3 2017 and 5 closed out, a net change of 0 holders.
- The largest BioLineRX buyer in Q3 2017 was BVF Inc, an estimated $8.79M added.
- The largest BioLineRX seller in Q3 2017 was Sabby Management, an estimated $2.51M sold.
Based on aggregated 13F filings for Q3 2017.